Smitha Holla, MD
Neurology · Madison, WINPI 1922386929
Payments from drug & device makers
Across 56 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$413
- Supernus Pharmaceuticals, Inc.$150
- Novartis$135
- Biogen$78
- EMD Serono, Inc.$42
- AbbVie$37
- plus $130 from 8 others
What the payments were for
- Speaking & faculty fees$222%
- Food & beverage$56257%
- Education$40141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $413 |
| Supernus Pharmaceuticals, Inc. | 23 | $150 |
| Novartis | 8 | $135 |
| Biogen | 5 | $78 |
| EMD Serono, Inc. | 3 | $42 |
| AbbVie | 2 | $37 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Lilly USA, LLC | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$985 in reported general payments places this provider in the 60th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 14 | $74,204 |
| AptiomEslicarbazepine Acetate | 12 | $17,751 |
| LamictalLamotrigine | 24 | $15,842 |
| TopamaxTopiramate | 12 | $12,435 |
| ValtocoDiazepam | 16 | $11,557 |
| Lacosamide | 71 | $10,524 |
| Levetiracetam | 191 | $7,354 |
| Divalproex Sodium ErDivalproex Sodium | 53 | $5,072 |
| Carbamazepine ErCarbamazepine | 27 | $3,166 |
| Lamotrigine | 163 | $2,502 |
| CarbatrolCarbamazepine | 20 | $2,363 |
| Clobazam | 35 | $2,251 |
| Levocarnitine | 13 | $2,029 |
| Levetiracetam ErLevetiracetam | 13 | $1,921 |
| Valproic AcidValproic Acid (As Sodium Salt) | 16 | $1,811 |
Paid to pharmacies, not to this prescriber.
Other neurology in Madison
- Ankush BhatiaMadison$983K
- Christopher LuzzioMadison$555K
- Elias Granadillo DeluqueMadison$462K
- Natasha FrostMadison$443K
- Michael SnyderMadison$284K
- Kathleen ShannonMadison$117K
- Michael FruchtMadison$82K
- Ali ZandiehMadison$61K
- Kelsey GageschMadison$60K
- Patrick BeltonMadison$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.